VIP Price Comparison

Live prices from 7 SA suppliers, from R490.00, compared side by side so you never overpay.

Immune signalling Prices checked
We compare prices & may earn a commission. We do not sell or supply any products. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

Best Price R490.00
Average R768.00
Highest R950.00
You Could Save 48%
5 results
Best Price
Save 48%
White Rabbit Labs logo

VIP 5mg

In Stock 5mg
R490.00
+ R120.00 delivery
Striata Labs logo

VIP 5mg

R550.00
In Stock 5mg Lab Tested
Save 42% + R150.00 delivery
Helix Collective logo
R900.00
In Stock 5mg
Save 5% + R170.00 delivery
Impact Nutrition logo
R950.00
In Stock 5mg
+ R250.00 delivery
Impact Nutrition logo
R950.00
In Stock 5mg
+ R250.00 delivery

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

VIP Profile

Extensively Studied

Vasoactive Intestinal Peptide | Neuropeptide

Overview

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.

Mechanism of Action

VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

Key Benefits

  • Potent vasodilation and blood pressure reduction
  • Strong anti-inflammatory effects
  • Immunomodulation (Th1-Th2 balance)
  • Neuroprotective effects
  • Bronchodilation
  • Cardioprotective (positive inotropic effects)
  • Insulin secretion enhancement (glucose-dependent)
  • Gut barrier and permeability regulation

Quick Stats

Typical Dose
50-100 mcg per dose (up to 200 mcg in research protocols)
Frequency
1-2 times daily due to very short 2-minute half-life
Cycle Duration
As prescribed for specific condition
Storage
Lyophilized powder: 2-8°C refrigerated; Reconstituted: use immediately (very short stability, ~2 minute half-life)

Molecular Information

Molecular Weight
3,326 Da
Length
28 amino acids
Type
Neuropeptide
Half-Life
1-2 minutes

Amino Acid Sequence

One-letter: HSDAVFTDNYTRLRKQMAVKKYLNSILN?
His
1

Histidine

Position 1

Ser
2

Serine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Val
5

Valine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asp
8

Aspartic Acid

Position 8

Asn
9

Asparagine

Position 9

Tyr
10

Tyrosine

Position 10

Thr
11

Threonine

Position 11

Arg
12

Arginine

Position 12

Leu
13

Leucine

Position 13

Arg
14

Arginine

Position 14

Lys
15

Lysine

Position 15

Gln
16

Glutamine

Position 16

Met
17

Methionine

Position 17

Ala
18

Alanine

Position 18

Val
19

Valine

Position 19

Lys
20

Lysine

Position 20

Lys
21

Lysine

Position 21

Tyr
22

Tyrosine

Position 22

Leu
23

Leucine

Position 23

Asn
24

Asparagine

Position 24

Ser
25

Serine

Position 25

Ile
26

Isoleucine

Position 26

Leu
27

Leucine

Position 27

Asn
28

Asparagine

Position 28

NH2
29

NH2

Position 29

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

Pulmonary Hypertension

Most Effective

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

Vasodilation

Most Effective

Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.

Cardiac Support

Effective

Coronary vasodilation with positive inotropic and chronotropic effects on the heart.

Neuroprotection

Moderate

Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders.

Autism Spectrum Disorders

Emerging

Potential therapeutic target being researched for ASD.

Circadian Rhythm

Moderate

Produced in suprachiasmatic nuclei; involved in circadian regulation.

Diabetes Support

Moderate

Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk.

Anti-Inflammatory

Effective

Potent anti-inflammatory effects useful in IBD and autoimmune conditions.

Sarcoidosis

Moderate

Therapeutic potential for pulmonary and systemic sarcoidosis.

Dosing Protocols

injectable

VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent.

Goal Dose Frequency Route
General use 50-100 mcg 1-2x daily SubQ or IV
Research protocols 100-200 mcg As directed SubQ or IV

Key Tips

  • Very short half-life (~2 minutes)
  • Multiple daily doses may be needed
  • Analogs offer improved stability
Materials Needed
Bacteriostatic water (BAC) Insulin syringes Alcohol swabs Peptide vial Sterile work surface
Steps
  1. 1 Clean work area and hands thoroughly
  2. 2 Calculate required BAC water volume
  3. 3 Draw BAC water into syringe
  4. 4 Inject slowly down vial side
  5. 5 Gently swirl until dissolved (never shake)
  6. 6 Use promptly due to short stability

nasal

Inhalation route researched for pulmonary hypertension. Safety demonstrated in healthy and asthmatic subjects at 100 μM concentrations.

Goal Dose Frequency Route
Pulmonary hypertension 100-200 mcg/day Daily (inhaled) Inhalation

Key Tips

  • Targeted delivery to lungs
  • Effective for pulmonary conditions
  • Non-invasive

Peptide Interactions

BPC-157

Compatible

No known negative interactions; different mechanisms.

Thymosin Alpha-1

Synergistic

Both have immunomodulatory effects; may complement each other.

LL-37

Compatible

Both have anti-inflammatory properties.

What to Expect

Minutes

Rapid vasodilation and hemodynamic effects

Hours

Anti-inflammatory signaling activated

Days-Weeks

Cumulative effects on inflammation and immune balance

Ongoing

Sustained benefits with regular administration

Side Effects & Safety

Common Side Effects

  • Vasodilation (flushing, warmth)
  • Hypotension
  • Increased heart rate
  • Gastrointestinal effects (diarrhea possible)
  • Headache

Stop Signs

  • Severe hypotension
  • Allergic reaction symptoms
  • Severe diarrhea
  • Cardiac arrhythmias

Contraindications

  • Severe hypotension
  • VIPoma or related tumors
  • Pregnancy or breastfeeding
  • Severe cardiac conditions

Quality Checklist

Good Signs

  • White lyophilized powder
  • Clear solution after reconstitution
  • Intact vacuum seal

Warning Signs

  • Use quickly after reconstitution (unstable)

Bad Signs

  • Discolored powder
  • Cloudy solution
  • Particulates visible

Research & References

Key References

  1. 2003

    VIP as New Drug for Treatment of Primary Pulmonary Hypertension

    Journal of Clinical Investigation

    VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity.

  2. 2022

    Therapeutic Potential of VIP and VPAC2 in Type 2 Diabetes

    Frontiers in Endocrinology

    VIP promotes glucose-dependent insulin secretion via VPAC2, reducing hypoglycemia risk.

  3. 2010

    Therapeutic Potential of VIP in Neurological Disorders

    CNS Neuroscience & Therapeutics

    VIP and receptors are promising therapeutic targets for AD, PD, and autism spectrum disorders.

  4. 2011

    VIP Structure and Function for Therapeutic Applications

    Pharmacology & Therapeutics

    Comprehensive review of VIP receptor signaling and therapeutic applications.

Search PubMed for VIP

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

No spam. Unsubscribe anytime. We respect your privacy.